CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ovarian Cancer

This study — called CATALINA-4 — is testing a new drug called TORL-1-23 given alongside standard chemotherapy before surgery in women with advanced ovarian cancer. The drug targets a protein called claudin-6 (CLDN6) that is found on many ovarian cancer cells, and researchers hope it can shrink tumors enough to make surgery more effective. **You may be eligible if...** - You have been diagnosed with advanced epithelial ovarian, primary peritoneal, or fallopian tube cancer (Stage III or IV) - Your tumor tests positive for the claudin-6 (CLDN6) protein - You have not yet received any treatment for this cancer - You have not had prior surgery or radiation to the abdomen or pelvis - You are in reasonably good health (ECOG performance status ≤ 2) **You may NOT be eligible if...** - You have a rare subtype of ovarian cancer (clear cell, mucinous, sarcomatous, low-grade/borderline, or non-epithelial) - You have received prior treatment for this cancer - You have active or worsening brain metastases - You are pregnant or breastfeeding - You have serious uncontrolled medical conditions or active infections Talk to your doctor to see if this trial is right for you.